We therefore hypothesize that the presence of < 9.4% SIRPα/β+memory B cells in RA patients prior to initiation of adalimumab treatment could be used as biomarker to predict ADA development in these patients. This evidence concerns the gene SIRPA and rheumatoid arthritis.